Meridian Bioscience Net Tangible Assets

As of the most recent data (December 2022), VIVO shows a net tangible assets of $340M. That compares with $150M in the prior-year period — up 128.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, VIVO's net tangible assets is now $340M (was $150M) — a 128.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Meridian Bioscience is outperforming or lagging.

Tracking VIVO's net tangible assets over time shows whether Meridian Bioscience is scaling, shrinking, or reshaping that part of the business. The current reading is $340M That compares with $150M in the prior-year period — up 128.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net tangible assets page, Stockcircle has Meridian Bioscience's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $340M) with ownership activity and broader fundamentals.

Meridian Bioscience's net tangible assets is $340M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.